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Summary
In the current issue, two articles highlight the impact of MITF on melanoma development. In the
first, Lister et al. (2013) reveal in vivo proof of MITF directly regulating tumor development in
BRAFV600E melanomas. In the second, Sturm et al. (2013) present a clinical trial that emphasizes
the importance of the recently discovered E318K MITF germline mutation in patients with
multiple primary melanomas.
MITF and its role in BRAFV600E melanoma
The master melanocyte transcription factor (MITF) is a member of the microphthalmia-
related transcription factor (MiT) family, and it plays key roles in survival, growth and
differentiation of melanocytes, retinal pigment epithelium, osteoclasts and other
hematopoietic lineages (Haq and Fisher, 2011). Several MiT family members, in addition to
MITF, have been associated with cancer—specifically TFE3 (in renal carcinomas and
Alveolar Soft Parts Sarcoma) and TFEB (in renal carcinomas). Upstream and downstream
alterations of MITF are known to change melanoma phenotype and function. Both, high and
low MITF expression levels have been associated with melanoma development.
Recently, the complex interactions among genetic and environmental factors in melanoma
have been a focus of intense research. About 50% of melanoma patients exhibit somatic
mutations in the BRAF gene coding for the B-Raf serine/threonine kinase involved in the
Ras/Raf–mitogen-activated protein kinase pathway. So far, over 30 different BRAF
mutations are known to exist, although BRAFV600E is by far the most common mutation. Its
discovery was followed by successful application of small molecule inhibitors in clinical
trials (Flaherty et al., 2012), although drug resistance remains a problem. Since the
discovery of MITF’s oncogenic amplification in human melanomas (Garraway et al., 2005)
and the in vitro studies that corroborated a potential interplay of BRAF and MITF
(Wellbrock and Marais, 2005), recent studies have assigned BRAFV600E a critical role in
sustaining MITF activity at an intermediate level, enabling tumor growth (Hoek and Goding,
2010). However, in vivo analyses have thus far been lacking.
The published work of Lister et al. (2013) begins to close this gap. A temperature-sensitive
mitfavc7 mutant allele enables MITF activity to be varied within an individual animal by
altering water temperature. The mitfavc7 allele is a splice site mutation at the intron 6 splice
donor site inducing a reduction in melanocyte numbers when zebrafish are reared at less
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tthan 26°C, and an almost complete loss of melanocytes at a temperature higher than 28°C.
Lister and coworkers crossed this mitfavc7 mutant zebrafish with a transgenic BRAFV600E
fish to generate BRAFV600E/V600Emitfavc7/vc7 (BRAFV600Emitf) animals. Comparing
BRAFV600Emitf zebrafish with BRAFV600E/V600Ep53M215K/M215K (BRAFV600Ep53) fish,
BRAFV600Emitf mutants showed an expression of the intron 6 mutated mitfa transcript and
an almost complete loss of the mitfa transcript. BRAFV600Emitf mutants, when exposed to
low levels of MITF, developed pigmented lesions; in 18 out of 67 fish they progressed to
melanomas, a melanoma incidence similar to that found in BRAFV600Ep53 zebrafish
(48/177). Not surprisingly, in vivo abrogation of MITF revealed an impressive tumor
regression in 12 out of 15 fish after 8 weeks. Complete tumor regression occurred in 6 of the
12, as indicated by melanophage infiltration and increased apoptosis in tumor tissues.
However, after increasing MITF levels the tumors relapsed at the previous sites. Taken
together, these data strongly suggest direct interaction between MITF and growth/survival of
BRAFV600E melanomas, as well as a key survival role for MITF within BRAFV600E-driven
melanomas.
The E318K Mutation in Melanoma
So far, relatively few mutations have been liked to familial melanoma. In addition to
CDKN2A and CDK4, a human germline mutation of MITF has now been identified.
Performing whole-exome sequencing of patients from several melanoma families,
Yokoyama et al. (2011) identified an individual carrying a germline variant (coding DNA
sequence c.G1075A; protein sequence p.E318K; rs149617956) in MITF. Linkage analysis
of 31 families subsequently identified to carry the variant, generated a log of odds score of
2.7 under a dominant model, indicating E318K as a possible intermediate risk variant.
Large-scale screening of an Australian cohort confirmed the impact of the E318K variant.
Whereas the MITF E318K variant was found in 14 out of 1,953 controls, it was present in
34 of the 2,059 patients. The MITF E318K variant was particularly augmented in cases
displaying multiple primary melanomas and in those with a family history of melanoma.
Consistent with a gain-of-function state for MITF, the variant was also reported to be
associated with non-blue eye color. The gain-of-function was shown to correspond to loss of
a previously described SUMOylation site at Codon 318 on MITF (Miller et al., 2005), which
is otherwise antagonistic to MITF’s transcriptional function. Subsequent replication of these
findings in two independent population-based case-control samples from the U.K. confirmed
that the MITF E318K variant occurred much more commonly in cases than controls.
Bertoletto et al. (2011) sequenced the MITF gene in 62 patients with both melanoma and
renal cell cancer and discovered the same heterozygous germline mutation resulting in
substitution of glutamic acid 318 with lysine (E318K) as well as similar alterations in MITF
SUMOylation and transcriptional activity. Later, an Italian study examined 667 melanoma
patients, revealing a 3-fold higher risk for developing melanoma, and a 6.4-fold higher risk
for developing multiple primary melanomas for MITF E318K carriers compared to control
populations. Furthermore, this mutation has been associated with an increased nevus number
and non-blue eye color. Additionally, carriers with a personal and/or family history of
pancreatic cancer and kidney patients seemed to suffer from a significantly higher risk of
developing melanoma (Ghiorzo et al., 2012). However, a clear phenotypic characterization
of nevi and tumor patterns in MITF E318K melanoma patients has been lacking so far.
In the current issue Sturm et al. (2013) screened 288 volunteer patients for the MITF E318K
mutation and identified six carriers. Whereas all of these patients were fair skinned and had
suffered from multiple primary melanomas, none showed a mutation in the CDK2A locus
and two out of the six patients were found to be red haired MC1R R/R homozygotes. Eye
imaging revealed an almost equal number of blue and non-blue eye color carriers.
Furthermore, patients carrying the MITF E318K mutation showed a significantly higher
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tnumber (p=0.008) of nevi larger than 5mm. Out of the total of 13 melanomas excised from
the E318K carriers, histopathology identified 4 amelanotic melanomas. The corresponding
incidence of 30% was clearly higher than the generally reported frequency of 2 to 8%,
suggesting a possible impact of the MITF E318K mutation on the development of
amelanotic tumors. As 3 4 melanomas were obtained from a MITF E318K carrier patient
showing a MC1R homozygous R/R genotype, suggesting that interplay of MITF E318K
mutants and MC1R variants might contribute to the formation of melanomas, especially
amelanotic melanomas. However, further large-scale studies are needed.
Taken together, these translational studies highlight the crucial impact of MITF on
melanoma risk and development. In 2010, a phase one study evaluating drug tolerance of an
histone deacetylase inhibitor inhibitor, shown to suppress MITF expression (Yokoyama et
al., 2008) was initiated (http://www.clinicaltrials.gov, Identifier: NCT01065467, accessed
10 August 2013). Further identification of MITF modulating small molecules and a better
understanding of the cellular and molecular relationship between MC1R variants, E318K
and BRAF/NRAS mutations will be necessary to fully understand MITF’s role(s) in
melanoma pathogenesis and to optimize strategies from bench to bedside.
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tClinical Implications
• Screening for CDKN2A, CDK4, and the recently discovered E318K mutation
should be performed in all patients presenting with a history of familial
melanomas or a history of multiple primary melanomas, due to the potential
ability to identify family members with elevated risk.
• Regarding melanoma development, and especially in amelanotic melanomas,
special attention should be paid to MC1R-mutant red haired patients bearing the
E318K mutation.
• In a zebrafish model, abrogation of MITF activity in BRAFV600E melanomas
revealed complete melanoma regression, highlighting possible therapeutic
opportunities for humans. Further investigation of small molecule modulators of
MITF may lead to useful methods of screening and treatment.
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